Last reviewed · How we verify
Leuplin or zoladex
Leuprolide and goserelin are GnRH agonists that suppress luteinizing hormone and follicle-stimulating hormone, leading to suppression of testosterone and estrogen production.
Leuprolide and goserelin are GnRH agonists that suppress luteinizing hormone and follicle-stimulating hormone, leading to suppression of testosterone and estrogen production. Used for Advanced prostate cancer, Breast cancer (premenopausal women), Endometriosis.
At a glance
| Generic name | Leuplin or zoladex |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These drugs bind to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by downregulation and sustained suppression of these hormones. This results in castration-level testosterone suppression in males and estrogen suppression in females, making them effective for hormone-dependent cancers and certain reproductive disorders.
Approved indications
- Advanced prostate cancer
- Breast cancer (premenopausal women)
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Erectile dysfunction
- Decreased libido
- Injection site reaction
- Headache
- Bone density loss (osteoporosis)
- Gynecomastia
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (PHASE2)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leuplin or zoladex CI brief — competitive landscape report
- Leuplin or zoladex updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI